Cargando…

One-carbon cycle alterations induced by Dyrk1a dosage

Hyperhomocysteinemia due to cystathionine beta synthase deficiency confers diverse clinical manifestations. It is characterized by elevated plasma homocysteine levels, a common amino acid metabolized by remethylation to methionine or transsulfuration to cysteine. We recently found a relationship bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delabar, Jean-Maurice, Latour, Alizée, Noll, Christophe, Renon, Marjorie, Salameh, Sacha, Paul, Jean-Louis, Arbones, Mariona, Movassat, Jamileh, Janel, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121348/ https://www.ncbi.nlm.nih.gov/pubmed/27896129 http://dx.doi.org/10.1016/j.ymgmr.2014.11.004

Ejemplares similares

Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia
por: Latour, Alizée, et al.
Publicado: (2015)

DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase
por: Noll, Christophe, et al.
Publicado: (2009)

Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A
por: Guedj, Fayçal, et al.
Publicado: (2009)

Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease
por: Janel, N, et al.
Publicado: (2017)

Plasma DYRK1A as a novel risk factor for Alzheimer's disease
por: Janel, N, et al.
Publicado: (2014)

DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease
por: Barallobre, M J, et al.
Publicado: (2014)

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome
por: Najas, Sònia, et al.
Publicado: (2015)

Hypothesis and Theory: Circulating Alzheimer's-Related Biomarkers in Type 2 Diabetes. Insight From the Goto-Kakizaki Rat
por: Movassat, Jamileh, et al.
Publicado: (2019)

Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets
por: Hamzé, Rim, et al.
Publicado: (2022)

Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup(®) Dietary Supplement: Role of Green Tea Catechins
por: Gu, Yuchen, et al.
Publicado: (2020)

Metabolic Diseases and Down Syndrome: How Are They Linked Together?
por: Moreau, Manon, et al.
Publicado: (2021)

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases
por: Delabar, Jean M., et al.
Publicado: (2023)

Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice
por: Postic, Guillaume, et al.
Publicado: (2023)

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives
por: Neumann, Fernanda, et al.
Publicado: (2018)

DYRK1A Overexpression in Mice Downregulates the Gonadotropic Axis and Disturbs Early Stages of Spermatogenesis
por: Dard, Rodolphe, et al.
Publicado: (2021)

Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells
por: Kurabayashi, Nobuhiro, et al.
Publicado: (2013)

Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice
por: Souchet, Benoît, et al.
Publicado: (2019)

Altered age‐linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT‐preAD study) with high brain amyloid load
por: Delabar, Jean M., et al.
Publicado: (2020)

Impaired macroglial development and axonal conductivity contributes to the neuropathology of DYRK1A-related intellectual disability syndrome
por: Pijuan, Isabel, et al.
Publicado: (2022)

Craniofacial dysmorphology in Down syndrome is caused by increased dosage of Dyrk1a and at least three other genes
por: Redhead, Yushi, et al.
Publicado: (2023)

Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome
por: Atas-Ozcan, Helin, et al.
Publicado: (2021)

Early-Life Origins of Type 2 Diabetes: Fetal Programming of the Beta-Cell Mass
por: Portha, Bernard, et al.
Publicado: (2011)

Mother or Father: Who Is in the Front Line? Mechanisms Underlying the Non-Genomic Transmission of Obesity/Diabetes via the Maternal or the Paternal Line
por: Portha, Bernard, et al.
Publicado: (2019)

FastGrow: on-the-fly growing and its application to DYRK1A
por: Penner, Patrick, et al.
Publicado: (2022)

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome
por: Duchon, Arnaud, et al.
Publicado: (2016)

Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models
por: Souchet, Benoit, et al.
Publicado: (2019)

Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass
por: Portha, Bernard, et al.
Publicado: (2011)

P2-type purinergic signaling in the regulation of pancreatic β-cell functional plasticity as a promising novel therapeutic approach for the treatment of type 2 diabetes?
por: Mesto, Nour, et al.
Publicado: (2022)

Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for the Dual Specificity Tyrosine-Regulated Kinase-1A (Dyrk1A)
por: Arqué, Glòria, et al.
Publicado: (2008)

Overexpression of Dyrk1A Is Implicated in Several Cognitive, Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down Syndrome
por: García-Cerro, Susana, et al.
Publicado: (2014)

Mutational analysis of two residues in the DYRK homology box of the protein kinase DYRK1A
por: Widowati, Esti Wahyu, et al.
Publicado: (2018)

Mechanisms of KGF Mediated Signaling in Pancreatic Duct Cell Proliferation and Differentiation
por: Uzan, Benjamin, et al.
Publicado: (2009)

Reduced up-regulation of the nitric oxide pathway and impaired endothelial and smooth muscle functions in the female type 2 diabetic goto-kakizaki rat heart
por: Desrois, Martine, et al.
Publicado: (2017)

DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B
por: Yousefelahiyeh, Mina, et al.
Publicado: (2018)

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B
por: Papenfuss, Marco, et al.
Publicado: (2022)

Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control
por: Becker, Walter
Publicado: (2012)

Developmental Defects in Trisomy 21 and Mouse Models
por: Delabar, Jean Maurice, et al.
Publicado: (2006)

DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis
por: Dierssen, M., et al.
Publicado: (2006)

Emerging roles of DYRK2 in cancer
por: Tandon, Vasudha, et al.
Publicado: (2021)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
por: Moreau, Manon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_68bd5cmsevhi8k4uk9j3v2iarq